Earnings Feed
Start Free
Home/Filings/3/0000899243-20-020253
3//SEC Filing

MPM BioVentures 2014 LLC 3

Accession 0000899243-20-020253

CIK 0001808865other
View on SEC.govCompany Profile

Filed

Jul 22, 8:00 PM ET

Accepted

Jul 23, 7:21 PM ET

Size

37.5 KB

Accession

0000899243-20-020253

Insider Transaction Report

Form 3
Period: 2020-07-23
iTeos Therapeutics, Inc.ITOS
MPM BioVentures 2014, L.P.
Other
Holdings

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)
EVNIN LUKE
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)
Foley Todd
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)
MPM BioVentures 2014 (B), L.P.
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)
MPM Asset Management Investors BV2014 LLC
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)
MPM BioVentures 2014 LLC
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)
MPM BioVentures 2014 GP LLC
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)
MPM BIOVENTURES 2018, L.P.
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)
MPM BIOVENTURES 2018 (B), L.P.
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC
Other
Holdings

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (42,605 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (48,336 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,944 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (84,655 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (43,687 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (15,820 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (724,702 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (24,326 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (1,269,230 underlying)

  • Series B Preferred Stock

    (indirect: Footnote)
    → Common Stock (801,619 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (457,706 underlying)

  • Series B-2 Preferred Stock

    (indirect: Footnote)
    → Common Stock (9,033 underlying)
Footnotes (7)
  • [F1]Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  • [F2]The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 LP ("BV 2014") will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 (B) LP ("BV 2014(B)") will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 LP ("BV 2018") will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F3](Continued from footnote 2) The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 (B) LP ("BV 2018(B)") will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014 will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014(B) will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering.
  • [F4](Continued from footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018 will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018(B) will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020.
  • [F5]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("2014 BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of 2014 BV LLC and members of MPM Asset Management Investors BV2014 LLC.
  • [F6]MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("2018 BV LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). Luke Evnin, Ansbert Gadicke, Todd Foley and Edward Hurwitz are the managing directors of 2018 BV LLC and members of MPM Asset Management Investors BV2018 LLC.
  • [F7]Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Documents

1 file

Issuer

iTeos Therapeutics, Inc.

CIK 0001808865

→
Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001765021

Filing Metadata

Form type
3
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 7:21 PM ET
Size
37.5 KB
View on SEC.gov